Initial

USPTO Issues Notice of Allowance to BRAINBox Solutions to Grant Broad U.S. Patent Covering Biomarkers that Correlate to MRI Neuroimaging Findings

Retrieved on: 
Friday, March 17, 2023

RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods. The patent is part of the company's extensive and growing intellectual property portfolio covering the use of novel biomarkers in combination with functional tests to diagnose individuals with concussion (mild traumatic brain injury or acute traumatic encephalopathy, ATE) and assess their risk of chronic injury.

Key Points: 
  • RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.
  • "This new patent, and our broader portfolio, underlie the BRAINBox TBI family of diagnostic/prognostic point-of-care or main lab delivered tests we are developing for ATE," said Donna Edmonds, CEO of BRAINBox Solutions.
  • The Initial BRAINBox ATE test will include a panel of blood biomarkers and a battery of neurocognitive tests, combined in an easy-to-use application.
  • The new patent will cover the use of eight biomarkers, including Aldolase C (ALDOC) and Neurogranin (NRGN).

OPENDOOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Opendoor Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 10, 2023

Our investigation concerns whether the board of directors of Opendoor have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Opendoor have breached their fiduciary duties to the company.
  • Following the Merger, the Company has operated a digital platform for buying and selling residential real estate in the U.S.
  • Bloomberg’s findings evidenced the failure of Opendoor’s algorithm to adjust accurately to changing market conditions.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Bunker Hill Announces Pricing of Private Placement of Special Warrants

Retrieved on: 
Thursday, March 2, 2023

TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR; OTCQB: BHLL) is pleased to announce that it has priced its previously announced private placement (the “Offering”) of up to C$9 million of special warrants of the Company (the “Special Warrants”). The Special Warrants issuable by the Company pursuant to the Offering will be priced at C$0.12 per Special Warrant (the “Offering Price”). The Agents (as defined below) also have the option to sell up to an additional 15% of the Special Warrants sold pursuant to the Offering at the Offering Price, exercisable in whole or in part as determined by the Agents upon written notice to the Company at any time up to 48 hours prior to the final closing date of the Offering. The Offering Price was determined in the context of the market following discussions with the Agents.

Key Points: 
  • TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR; OTCQB: BHLL) is pleased to announce that it has priced its previously announced private placement (the “Offering”) of up to C$9 million of special warrants of the Company (the “Special Warrants”).
  • The Special Warrants issuable by the Company pursuant to the Offering will be priced at C$0.12 per Special Warrant (the “Offering Price”).
  • The Offering Price was determined in the context of the market following discussions with the Agents.
  • The Company intends to use the net proceeds of the Offering, if any, for working capital, general corporate purposes, and capital expenditures relating to the Bunker Hill Mine.

Summit Therapeutics’ Rights Offering Nearing Expiration Date

Retrieved on: 
Thursday, February 23, 2023

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the “Expiration Date”).

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the “Expiration Date”).
  • With respect to the rights offering, the Company has distributed non-transferable subscription rights to purchase up to 476,190,476 shares of common stock, for an aggregate offering value of up to $500 million.
  • The subscription rights will expire and have no value if they are not exercised prior to the Expiration Date.
  • The rights offering is made pursuant to the Company’s registration statement on Form S-3, which became effective on February 3, 2023, and the prospectus containing the detailed terms of the rights offering filed with the SEC.

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 7, 2023

In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.

Key Points: 
  • In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2022, Exelixis earned $33.9 million and $121.4 million, respectively, in royalty revenues.
  • Exelixis expects its partner Sairopa to file an Investigational New Drug application (IND) for ADU-1805 in the first quarter of 2023.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and full year of 2022 and provide a general business update during a conference call beginning at 5:00 p.m.

Nick Armstrong Named CAI's Initial Senior Director of Digital Enablement

Retrieved on: 
Friday, February 3, 2023

INDIANAPOLIS, Feb. 3, 2023 /PRNewswire/ -- Commissioning Agents Inc. (CAI) announced  Nick Armstrong has been named the Initial Senior Director of Digital Enablement, as CAI continues our investment in Digital Transformation for both our internal programs and our clients' operations.

Key Points: 
  • INDIANAPOLIS, Feb. 3, 2023 /PRNewswire/ -- Commissioning Agents Inc. (CAI) announced  Nick Armstrong has been named the Initial Senior Director of Digital Enablement, as CAI continues our investment in Digital Transformation for both our internal programs and our clients' operations.
  • Mr. Armstrong has 15 years of experience in the Biopharmaceutical, Food, and Personal Care industries – with innovation and digital enablement as the throughline.
  • The supply chain and regulatory complexities for this mission require a connected voice", Mr. Armstrong Nick explained.
  • "I'm excited to have Nick join the technology team and for the official establishment of Director of Digital Enablement role," stated Jackie Karceski, Chief Technology Officer of CAI.

Settlement agreement reached for Gottfriedson Band class

Retrieved on: 
Saturday, January 21, 2023

VANCOUVER, BC, Jan. 21, 2023 /CNW/ - Today, Band class representatives former Chief Shane Gottfriedson and former Chief Garry Feschuk, along with the Honourable Marc Miller, Minister of Crown-Indigenous Relations, announced that Canada has signed an agreement with the Representative Plaintiffs who represent the 325 members that have opted into the Gottfriedson Band class litigation.

Key Points: 
  • VANCOUVER, BC, Jan. 21, 2023 /CNW/ - Today, Band class representatives former Chief Shane Gottfriedson and former Chief Garry Feschuk, along with the Honourable Marc Miller, Minister of Crown-Indigenous Relations, announced that Canada has signed an agreement with the Representative Plaintiffs who represent the 325 members that have opted into the Gottfriedson Band class litigation.
  • Each Band class member will receive a share of annual investment income that is available.
  • The Court will consider whether the settlement is fair, reasonable and in the best interest of the class members.
  • Together, we have developed a settlement that will support the Band class members in their healing journeys for generations to come."

Acerus Files For CCAA Protection

Retrieved on: 
Thursday, January 26, 2023

TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”).

Key Points: 
  • TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”).
  • The Acerus Group sought creditor protection under the CCAA in order to receive a stay of proceedings that will allow the Acerus Group to work with the Monitor to facilitate the development of an orderly process designed to maximize the value of the Acerus Group’s assets, for the benefit of its creditors and other stakeholders.
  • The DIP Loan (as described below) is anticipated to fund the operations of the Acerus Group in the ordinary course during this process.
  • The Acerus Group intends to also file petitions commencing proceedings under Chapter 15 of the United States Bankruptcy Code at the United States Bankruptcy Court for the District of Delaware for creditor protection in the United States.

VERSES Receives Acceptance from NEO Exchange for Warrant Listing

Retrieved on: 
Monday, January 23, 2023

An aggregate of 11,613,485 Class A Warrants (the “Amended Warrants”) were subject to certain Warrant Amendments (as defined and described in the Initial Press Release).

Key Points: 
  • An aggregate of 11,613,485 Class A Warrants (the “Amended Warrants”) were subject to certain Warrant Amendments (as defined and described in the Initial Press Release).
  • The Amended Warrants will be posted for trading on the NEO at market open on January 24, 2023 under the symbol “VERS.WT.A”.
  • An aggregate of 6,487,229 Class A Warrants (the “Unlisted Warrants”) may become listed on the NEO once the Company’s receives written consent from the applicable warrant holders for the Warrant Amendments.
  • Prior to the Company listing a new batch of Unlisted Warrants after the initial Supplemental Listing, the Company will file a NEO Form 14A – Notice of an Additional Listing with the NEO.

Blackrock Silver Enters into Option Agreement with Tearlach Resources to Develop the Tonopah North Lithium Project

Retrieved on: 
Tuesday, January 10, 2023

Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.

Key Points: 
  • Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.
  • The exploration and development rights conferred to Tearlach under the Option Agreement in respect of the Tonopah North Project are exclusive to lithium minerals in the Optioned Zone.
  • Subject to the terms of the Option Agreement, Blackrock retains and reserves the rights to explore for, develop and mine all minerals (including gold and silver) other than lithium on the entire Tonopah North Project, including the Optioned Zone.
  • Upon Tearlach completing the Initial Earn-In and exercising the First Option, Tearlach and Blackrock Gold shall enter into a definitive mining joint venture agreement (the "Joint Venture Agreement") in respect of the management and ownership of the Optioned Zone of the Tonopah North Project (the "Joint Venture").